Criteria Systemic Sclerosis Panel
Also known as: SSC PANEL
Use
The Criteria Systemic Sclerosis Panel is indicated for patients with distinct features of systemic scleroderma/sclerosis (SSc). The presence of Scl-70 antibodies (also referred to as topoisomerase I, topo-I or ATA) is considered diagnostic for systemic sclerosis (SSc). RNA Polymerase III antibodies are used as an aid in the diagnosis of systemic sclerosis with increased incidence of skin involvement and renal crisis. Antinuclear antibodies (ANA) are a hallmark feature of systemic autoimmune rheumatic diseases, such as SARDs, and while they lack diagnostic specificity, they are associated with a variety of diseases, including cancers and autoimmune conditions.
Special Instructions
Not provided.
Limitations
Negative results do not necessarily rule out the presence of SSc. If clinical suspicion remains, additional testing may be needed. Scl-70 antibodies alone are detected in about 20% of SSc patients and have also been reported in patients with systemic lupus erythematosus, which may lead to a false-positive result. RNA polymerase III IgG antibody results can also yield false-positives due to non-specific binding of immune complexes.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
1.5 mL
Container
ARUP standard transport tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection and transfer to a transport tube.
Storage Instructions
Refrigerated
Causes for Rejection
Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month (avoid repeated freeze/thaw cycles) |
Other tests from different labs that may be relevant